News

The CHMP’s recommendation is for the use of LYNPARZA as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or

Luspatercept is an erythroid maturation agent (EMA), which has been designed to regulate late-stage red blood cell maturation. The drug is being jointly developed by Acceleron and Celgene

The indication the CHMP adopted is for TALZENNA as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth

SLE, simply referred as lupus, is a serious chronic disease that causes inflammation and damage to different body tissues and organs. The FDA provided priority review designation to

Relevance of the Study The purpose of the study is to explore using 68Ga-Tilmanocept as an aid in TB patient management while contributing to the better understanding of

In the monotherapy arm of the study, KEYTRUDA met a primary endpoint by demonstrating noninferiority to chemotherapy, the current standard of care, for overall survival (OS) in the

Stellar-3 is a randomized, double-blind and placebo-controlled trial, which assessed the safety and efficacy of selonsertib in patients with bridging fibrosis (F3) due to NASH. According to the

This recall is due to the detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) – found in six lots of active pharmaceutical ingredient (API) manufactured by Hetero Labs

Smart Pharma will operate Smart-ACT, a computational repurposed drug discovery, modeling and validation platform, which uses latest technology for systematic screening of existing approved drug molecules against certain